Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 13.77 +0.10 (+0.73%) Official Closing Price Updated: 7:00 PM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,454,810 Open 13.69 Bid (Size) 13.50 (1) Ask (Size) 13.94 (15) Prev. Close 13.67 Today's Range 13.69 - 13.79 52wk Range 12.57 - 16.39 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation July 24, 2024 Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... Via Benzinga Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst July 09, 2024 Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... Via Benzinga Performance YTD -3.97% -3.97% 1 Month +6.41% +6.41% 3 Month +4.56% +4.56% 6 Month -6.77% -6.77% 1 Year -9.76% -9.76% More News Read More Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Via Talk Markets Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report July 02, 2024 Via Benzinga Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Via Investor's Business Daily Topics Stocks Exposures US Equities Takeda Announces New Assignments of Directors June 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies June 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia June 22, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer June 21, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session June 18, 2024 Via Benzinga Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting June 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? June 17, 2024 Via Benzinga Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies June 17, 2024 Via Benzinga Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome June 17, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare June 15, 2024 Via Talk Markets Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) June 14, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts June 11, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire 7 F-Rated Stocks to Avoid at All Costs in June June 06, 2024 Via InvestorPlace Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report June 03, 2024 Via Benzinga Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo June 03, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma June 01, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) May 31, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings May 25, 2024 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.